Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.065.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.97% | -32.43% | -26.95% | -19.52% | -13.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.23% | -39.99% | -30.79% | -14.74% | -2.50% |
| Operating Income | 38.23% | 39.99% | 30.79% | 14.74% | 2.50% |
| Income Before Tax | 48.35% | 30.30% | 17.22% | 13.52% | 6.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.35% | 30.30% | 17.22% | 13.52% | 6.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.35% | 30.30% | 17.22% | 13.52% | 6.41% |
| EBIT | 38.23% | 39.99% | 30.79% | 14.74% | 2.50% |
| EBITDA | 38.35% | 40.74% | 31.50% | 15.27% | 2.81% |
| EPS Basic | 53.23% | 32.40% | 18.38% | 14.39% | 7.33% |
| Normalized Basic EPS | 48.56% | 48.70% | 34.76% | 29.03% | 15.45% |
| EPS Diluted | 53.27% | 32.51% | 18.53% | 14.15% | 7.21% |
| Normalized Diluted EPS | 48.56% | 48.70% | 34.76% | 29.03% | 15.45% |
| Average Basic Shares Outstanding | 10.42% | 5.41% | 2.07% | 1.06% | 0.98% |
| Average Diluted Shares Outstanding | 10.42% | 5.41% | 2.07% | 1.06% | 0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |